

## Report from the 7<sup>th</sup> Biennial Hatter Cardiovascular Institute Workshop: Cardioprotection – from novel targets to clinical application

Robert Bell, Reinier Beeuwkes, Hans Erik Botker, Sean Davidson, James Downey, David Garcia-Dorado, Derek J Hausenloy, Gerd Heusch, Borja Ibanez, Masafumi Kitakaze, Sandrine Lecour, Robert Mentzer, Tetsuji Miura, Lionel Opie, Michel Ovize, Marisol Ruiz-Meana, Rainer Schulz, Richard Shannon, Malcolm Walker, Jake Vinten-Johansen, Derek Yellon

### 1. Introduction

The 7<sup>th</sup> biennial Hatter Cardiovascular Institute workshop, comprising of 21 leading basic science and clinical experts, was held in South Africa in August 2012 to discuss the current cutting edge status of cardioprotection and the application of cardioprotective modalities in the clinical management of myocardial ischaemia/reperfusion injury in the context of acute coronary syndromes and cardiac surgery. The meeting, chaired by Professor Derek Yellon and Professor Lionel Opie, was run to a format of previous Hatter Cardiovascular workshops with data presented by proponents followed by discussion and debate by the faculty.

### 2. Novel therapeutic targets

#### 2.1. Microparticles in Cardioprotection

Sean Davidson and Derek Yellon described their recent foray into the burgeoning field of endogenous nanoparticles. These particles, exosomes and microparticles, are released into the blood from multiple cell types including activated platelets and epithelial and endothelial cells. They are thought to carry microRNA and mRNA with the potential for genetic exchange between cell types, as well as transport of signalosomes and even cell-surface receptors [1], all of which have the potential for delivering signals to the myocardium that modulate inflammation, angiogenesis or cardioprotection. They presented data confirming and quantifying the presence of these particles in rat and human plasma, and showed that administration of purified microparticles leads to attenuation of infarct size when administered to Langendorff-perfused rat heart and reduced cell death in cardiac-derived HL-1 cells subjected to simulated ischaemia/reperfusion. Fluorescently-labeled microparticles also show increased incorporation into HL-1 cells. Intriguingly, they also demonstrated that microparticle numbers can be altered under certain conditions [or “by certain treatments”], leading to their proposal that it may be possible to harness them for clinical purposes.

This preliminary work was considered very interesting, although a number of questions remained – particularly as to the parent cell-type of the microparticles released by remote conditioning and the efficacy of uptake within the myocardium. Moreover, at this time, it is unclear as to the mechanism of protection, but this is the subject of on-going study.

#### 2.2. Mitochondrial morphology

Derek Hausenloy and Derek Yellon presented the latest data looking at the role of mitochondrial morphology in the context of ischaemia/reperfusion injury, with the hypothesis that preventing mitochondrial fragmentation, or fission, during ischaemia/reperfusion injury would lead to a more

cardioprotected phenotype. In cardiac-derived HL-1 cells promotion of mitochondrial fusion proteins such as mfn-1 and mfn-2, or using a dominant negative mutation of the mitochondrial fission protein, Drp1, promoted mitochondrial fusion, and delayed the time to mitochondrial permeability transition pore (mPTP) opening in response to reactive oxygen species generating laser-light exposure in TMRM loaded cells. Similarly, a pharmacological inhibitor of Drp1 was found to be cardioprotective in the adult rat heart following ischaemia/reperfusion injury. Combined Mfn-1/Mfn-2 knockout adult hearts demonstrated increased mitochondrial fragmentation and the hearts demonstrated a dilated cardiomyopathy. Data was also shown examining the role of DJ-1 in the heart. Mutations in this protein induce mitochondrial dysfunction and are responsible for a genetic form of Parkinson's disease. Data was shown that over-expressing this protein in a cardiac cell-line induce mitochondrial elongation, delayed mPTP opening, and reduced cell death following simulated ischaemia/reperfusion injury. In the adult heart, the DJ-1 deficient heart had greater mitochondrial fragmentation concomitant with increased susceptibility to ischaemia/reperfusion injury. Interestingly, these hearts were also partially resistant to the protection elicited by ischaemic preconditioning.

The data was found to be very interesting, although the link between mitochondrial fusion and mPTP function is currently unclear – and there are technical challenges in terms of determining mitochondrial morphology in adult cardiac myocytes when compared to other cell types given the highly structured nature of the myocyte and multiple mitochondrial populations (subsarcolemmal, interfibrillar and perinuclear).

### **2.3. Platelets as a target for cardioprotection**

Antiplatelet therapy in the form of P2Y<sub>12</sub> inhibitors such as clopidogrel and prasugrel are an integral part of the immediate management of ACS. James Downey presented data that these agents have an additional pleiotrophic effects in the form of recruiting cardioprotective signalling that is dependent upon the presence of platelets, but independent of their impact upon platelet function and aggregation. These drugs, including the intravenous P2Y<sub>12</sub> inhibitor, cangrelor, demonstrably attenuate infarct size when administered before reperfusion – a protective effect dependent upon the recruitment of adenosine A<sub>2B</sub> receptors, signalling reactive oxygen species (ROS) formation, reperfusion injury salvage kinases (RISK) and mitochondrial K<sub>ATP</sub> (mK<sub>ATP</sub>). Interestingly, P2Y<sub>12</sub> inhibitors are not additive to ischaemic conditioning, suggesting a conditioning-like protective mechanism. Given clinical data showing the genuine benefits of adding P2Y<sub>12</sub> inhibitors to aspirin and heparin in the management of ACS (these agents themselves do not induce cardioprotection), leads to the speculation that there may be a clinical cardioprotective element to the benefits observed – above and beyond the antiplatelet effect for which these drugs were originally designed.

During the discussion of this data, it was observed that there had been a significant shift in the adoption of various P2Y<sub>12</sub> inhibitors during the lifetime of many of the clinical trials undertaken to study the efficacy of conditioning protocols – perhaps implicating a potential confounder to the outcome of more recent studies. This phenomenon would deserve further investigation and retrospective analysis of previous trial data to ascertain any impact of P2Y<sub>12</sub> inhibitors on infarct limitation.

#### **2.4. Matrix metalloproteinases and cardioprotection**

Matrix metalloproteinases (MMPs) have been extensively studied in the context of vascular injury and in ventricular remodelling following ischaemia/reperfusion injury. However, more recently, MMPs have been demonstrated to have intracellular targets – cytoskeletal[2, 3], contractile[4, 5] and potentially also in terms of cell survival and cell death pathways[6, 7]. Robert Bell and Derek Yellon presented data demonstrating that not only does MMP inhibition at reperfusion attenuate infarction in both in-vitro and in-vivo preparations, but the protection observed is additional to that seen following targeted deletion of the cyclophilin-D component of the mPTP. The pharmacological agent used, ilomastat, had no direct inhibitory effect upon mPTP opening in response to ROS exposure – further suggesting a conditioning-independent mechanism of protection. Interestingly, MMP inhibition with ilomastat did result in increased phosphorylation of Akt, ERK and serine 9 of GSK-3 $\beta$ . Whether this is mechanistic is currently unclear – and the discussion centred on potential mechanisms that could be further investigated in due course.

#### **2.5. Mitochondrial connexins**

Connexin (Cx) 43 has long been associated with gap junction function and is found associated with mitochondria as a consequence of preconditioning signalling. Rainer Schulz presented the latest data from his lab regarding the role of Cx43 in preconditioning signalling. The C-terminus of the Cx43 protein has been found to be the target for multiple post-translational modifications by kinase mediated phosphorylation (PKA, Src, MAPK, PKC, CKI and Akt) and S-nitrosylation. Recruitment of Cx43 appears to lead to mK<sub>ATP</sub> opening, and subsequent recruitment of preconditioning signalling through ROS generation. While Cx43 appears not to be involved in postconditioning, there is data to suggest that inhibition of Cx43 leads to a lower threshold to opening of the mPTP in response to calcium.

#### **2.6. Preconditioning mitochondria – implications for cardioprotection**

Marisol Rulz-Meana presented data revealing that it is possible to directly condition mitochondria in isolation of the intact myocyte, preserving complex 1 and 2 function, mimicking the mitochondrial respiratory preservation seen in intact heart following ischaemic preconditioning. The ability to preserve complex 1 respiration in mitochondria was independent of mK<sub>ATP</sub> function and was still evident even in mitochondria isolated from cyclophilin-D knock out hearts. Interestingly, the data demonstrated that differing mitochondrial populations had variable capacity to be preconditioned, which appeared to correlate with the presence or absence of Cx43: Cx43 is largely found in subsarcolemmal mitochondria which can be conditioned, versus the relatively deplete interfibrillar mitochondria which demonstrated little capacity to preserve complex 1 and 2 respiration following conditioning. Moreover, Cx43 knockouts show no preservation of complex 2 respiration following ischaemic preconditioning.

The mechanism of mitochondrial conditioning was unclear: during the discussion oxidative modification of a cysteine residue of Cx43 during preconditioning was speculated along with the suggestion that there may still be kinase signalling activity within isolated mitochondria that may go some way to explaining the alterations of oxidative metabolism within preconditioned mitochondria.

#### **2.7. Beta blockade and cardioprotection**

The role of beta blockers and cardioprotection had been investigated in the past, and the data at that time felt unconvincing, but new work from Borja Ibanez's group suggests a new direction in

studying a potentially cardioprotective role for beta blockade in ischaemia/reperfusion injury. In recent work, intravenous metoprolol was found to attenuate ischaemia/reperfusion injury concomitant with phosphorylation of Akt and attenuation of caspase-3. The postulated explanation for this protective effect was through activation of a recently characterised  $\beta_3$   $G_{i/o}$ -coupled receptor, activation of which has been shown to increase the bioavailability of nitric oxide through endothelial nitric oxide synthase. Data was presented revealing that  $\beta_3$  agonists result in significant attenuation of ischaemia/reperfusion injury (improved salvage index by cardiac magnetic resonance imaging (CMR)), improved left ventricular ejection fraction through both echo and CMR in pig, and similar improvements in viability seen in isolated cardiac myocytes. In mouse, knockouts of  $\beta_3$  show no such protection.

During the discussion, it was noted that similar results have also been seen using nebivolol[8], which recruits nitric oxide synthesis through  $\beta_3$  receptor activation. Curiously both the data presented and the nebivolol study appear in contrast to earlier data using various beta blockers (summarised by Hearse, Yellon and Downey[9]), and the reason for the anomaly remains unclear. Other questions arose regarding the density of  $\beta_3$  receptors in human myocardium, which at the present time is unknown, but work continues to further characterise this potential mechanism of protection and the potential clinical benefits in man.

### **3. Translating cardioprotection for clinical benefits**

#### **3.1. Insulin as an agent to protect against ischaemia-reperfusion injury**

Lionel Opie presented an overview of metabolic therapy for acute myocardial infarction: following acute anterior injury, adrenergic overdrive switches the substrate for myocardial metabolism from glucose to free fatty acids, which is deleterious in terms of long term myocardial viability. Sodi-Pallares et al were amongst the first to describe the benefits of glucose/insulin/potassium (GIK) therapy in the context of acute myocardial infarction in 1962,[10] and has been an area of interest revisited many times over the following decades. One key aspect of insulin therapy however is the need for it to be administered early. In the recently reported Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care (IMMEDIATE) Trial[11], GIK was administered prior to admission to hospital in the ambulance and continued for 12 hours thereafter, and therefore present during early reperfusion. While the trial failed to meet its primary endpoint of progression to myocardial infarction, there was a significant reduction in the secondary endpoint, the composite of prehospital or in-hospital cardiac arrest or in-hospital mortality: 6.1% with GIK versus 14.4% with placebo (OR, 0.39; 95% CI, 0.18-0.82; P = .01).[11] Glucose, glucose/insulin and glucose/insulin/potassium has been found to be protective in all species studied, including man, with benefits too in terms of preservation of sinus and sino-atrial node function[12].

The key point during the discussion of this presentation was the need for very early administration required for insulin's efficacy – both in terms of correcting the acute metabolic reaction to myocardial infarction, and in terms of recruitment of protective signalling cascades and modulation of mPTP opening.

#### **3.2. Preconditioning – where do we go from here?**

Ten years since presenting the original data showing the experimental evidence of ischaemic preconditioning, Jake Vinten-Johansen reviewed the data showing how this phenomenon has

progressed from the bench to the bed side, with evidence that not only does postconditioning result in attenuation of cell death by reducing by necrosis and apoptosis, but also ameliorates neutrophil adherence and microvascular obstruction through RISK pathways and inhibition of mPTP opening. Recent data has also inferred the presence of a delayed postconditioning phenomenon,[13, 14] and further exploration and characterisation of this phenomenon is required which may represent a later onset of inflammation and neutrophil infiltration. In terms of future targets for cardioprotection, the interaction between endothelium, neutrophils and platelets were discussed in terms of attenuating microvascular obstruction and post-infarction inflammation. The potential development of catheter-based devices for deploying ischaemic postconditioning and myocardial hypothermia were suggested as novel new technologies to induce cardioprotection in patients undergoing primary percutaneous intervention.

The discussion centred on the proposed model of two waves of reperfusion injury, with the late phase being mediated by inflammatory and gene-transcription mediated cell damage, which could be amenable to a late postconditioning protocol. It was suggested that work be transferred to a larger animal model, as small rodents were felt to exhibit very rapid resolution of injury, and therefore more likely to be reflective of the injury observed following acute myocardial infarction in man.

### **3.3. DPPiV inhibitors and GLP-1 analogues – novel cardioprotective and antidiabetic agents**

Richard Shannon presented data regarding DPPiV inhibitors and GLP-1 analogues, which independent of their anti-diabetic properties, appear capable of inducing cardioprotection via g-protein coupled receptors that also demonstrate  $G_s/G_i$  switching through  $\beta$ -arrestin. GLP-1 appears negatively inotropic, independent of glucose uptake. Interestingly, two peptide analogues, 7-36 and 9-36, demonstrate differing properties which were either p38 MAPK dependent/NO independent or p38MAPK independent/NO dependent respectively. Both markedly attenuated free fatty acid utilisation by mitochondria without alteration of state 3 respiration, and also demonstrate some evidence of mitochondrial respiratory chain uncoupling. Interestingly, DPPiV inhibition was not cardioprotective at levels of normoglycaemia, unlike the protective properties of GLP-1 to improve post-ischaemic contractile recovery (REF)?.

These classes of agents would appear to have considerable potential in the management of both diabetes and in cardioprotection. Whether DPPiV inhibitors would be cardioprotective in conditions of hyperglycaemia is currently unknown.

### **3.4. Ischaemic and pharmacological postconditioning: clinical application**

Reinier Beeuwkes started this session describing a novel substance, CMX-2043, a lipoic acid, that appears to have cardioprotective properties through recruitment of Akt. CMX-2043 has recently been through phase 2a trial and shown to be safe in the context of elective percutaneous intervention, and demonstrated some promise in attenuating troponin-release when administered 15-120minutes prior to the intervention.

David Garcia-Dorado provided an up-date on the soon to be reported Myocardial Protection With Adenosine During Primary Percutaneous Coronary Intervention in patients With STEMI (PROMISE) trial (clinical trial number NCT00781404). Designed to evaluate the safety and efficacy of a brief intracoronary infusion of adenosine administered at the time of reperfusion, and to assess the drug's

efficacy to limit infarct size and left ventricular remodelling in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction, this multicentre, prospective, randomised, placebo-controlled, double-blind study recruited 200 patients older than 18 with ST elevation, without prior myocardial infarction receiving primary PTCA within 6 hours after symptom onset. Infarct size and risk zone will be assessed by CMR, and change of left ventricular ejection fraction and end diastolic diameter assessed at 6 months. Only very preliminary data was available by the time of the workshop, but the full data set is expected to be available by September 2012.

The Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients (CIRCUS) trial update was presented by Michel Ovize (trial number NCT01502774). This is a multicentre, randomised and double blinded trial designed to compare cyclosporine versus placebo administered as an intravenous bolus prior to restoration of blood flow by percutaneous intervention. The study investigators are currently recruiting at 1 per month, with over 400 patients already recruited and enrolment is expected to continue for another year. The primary end-point is combined incidence of total mortality, hospitalization for heart failure and LV remodeling (defined as an increase of LV end-diastolic volume > 15% by transthoracic echocardiography), with secondary end-points including all-cause mortality, cardiovascular death, heart failure, unstable angina or stroke.

Hans Erik Bøtker presented an update on the Effect of Remote Preconditioning in Primary Percutaneous Intervention of Acute ST Elevation Myocardial Infarction (CONDI) trial (NCT00435266). This randomised single blinded trial used a pressure cuff inflations to induce remote conditioning (4 cycles of 5 minutes ischaemia, 5 minutes reperfusion) in the transit ambulance prior to the arrival at the primary intervention centre following diagnosis of ST elevation myocardial infarction. The investigators recruited 333 patients divided into treatment and placebo groups (167 and 166 respectively). Median salvage index was 0.75 (IQR 0.50–0.93, n=73) in the remote conditioning group versus 0.55 (0.35–0.88, n=69) in the control group, with median difference of 0.10 (95% CI 0.01–0.22; p=0.0333); mean salvage index was 0.69 (SD 0.27) versus 0.57 (0.26), with mean difference of 0.12 (95% CI 0.01–0.21; p=0.0333). Moreover, there was an improvement in improvement in major adverse coronary and cerebral events (MACCE) in the RIPC group, presenting as an initial benefit and persisting over the subsequent 2 years. Therefore, it was found that remote ischaemic conditioning before hospital admission increased myocardial salvage, and had a favourable safety profile.

The Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery (ERICCA) trial was presented by Derek Hausenloy. This randomised, single-blinded, multicentre clinical trial compared 4 cycles of 5 minutes ischaemia, 5 minutes reperfusion of the upper limb induced by pressure cuff inflation, prior to cardiac surgery (coronary artery bypass ± valve replacement), with the primary outcome of combined Cardiovascular Death, MI, Revascularisation and Stroke. Secondary end-points include peri-operative myocardial injury, LV ejection fraction, acute kidney injury, all-cause death, length of ITU stay and quality of Life. So far, the investigators had recruited 382 out of a targeted 1600 patients over 18 sites, with the aim to complete recruitment by October 2013, with results anticipated by December of that year.

### **3.5. Analysis of existing clinical evidence for conditioning**

Gerd Heusch undertook to look at the translational clinical data centring upon cardioprotection and conditioning. Interestingly, of the clinical studies identified, almost all show an improvement of

cardiac enzyme release in the context of ischaemic preconditioning in coronary artery bypass grafting, ischaemic postconditioning in percutaneous intervention for ST elevation MI and remote ischaemic conditioning for both coronary artery bypass grafting and percutaneous intervention. The one common element identified underlying negative trial data in surgery was the concomitant use of propafol. Other typical confounders that may influence clinical outcome are co-morbidities such as diabetes, but an overlooked factor is the coronary vasculature both in terms of function and pathology: slow reperfusion is itself cardioprotective, and microembolisation (that occurs following dispersal of the occlusive coronary thrombus) can attenuate preconditioning's protection. [15] Experimental microembolisation with inert microspheres of 40 µm diameter, can increase infarct size by up to 15%, predominantly through deposition in the border zone surrounding the infarcted myocardium, although interestingly ischaemic postconditioning tends to ameliorate microsphere border zone deposition, perhaps suggesting preservation of microvascular function.

While ischaemic conditioning appears to have robust supporting clinical data, pharmacological conditioning, except where the end-effector, the mPTP, has been targeted (cyclosporine), has been rather disappointing. It was speculated that the transient ischaemic stimulus is more likely to recruit the full conditioning response, rather than a highly selective pharmacological trigger which may recruit only limited signalling.

Over all, it was felt that many of the early phase 2 and 3 trials of ischaemic conditioning had shown great promise, and perhaps the lack of general clinical adoption of conditioning was rather more dependent upon the lack of significant clinical outcome trials – a void that hopefully will be filled once the current on-going clinical trials (as mentioned above) are reported.

#### **4. Conclusions**

The workshop has offered a preview of a number of original approaches to tackle cardioprotection in the future, from novel concepts in signal transmission both in the context of remote conditioning and platelet-derived signalling, through mPTP-independent cardioprotective signalling, to mitochondrial recruitment as an end-effector in the experimental setting – both in terms of mPTP function and mitochondrial morphology. In clinical translation, there are a number of exciting trials currently undergoing recruitment and provide hard primary outcome data that will hopefully provide evidence that conditioning is an efficacious approach in man that will add to the data already coming from completed trials that have been discussed. Overall, the participants were optimistic regarding the future of cardioprotection as a potential useful tool in the management of patients with myocardial ischaemia, to further augment the interventions and therapies already available to the clinician.

#### **5. References**

- [1] Amabile N, Rautou PE, Tedgui A, Boulanger CM. Microparticles: key protagonists in cardiovascular disorders. *Seminars in thrombosis and hemostasis*. 2010;36:907-16.
- [2] Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. *Circulation*. 2011;122:2039-47.
- [3] Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-Lopez NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. *Journal of molecular and cellular cardiology*. 2007;43:429-36.

- [4] Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. *Circulation*. 2002;106:1543-9.
- [5] Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. *Circulation*. 2005;112:544-52.
- [6] Kandasamy AD, Schulz R. Glycogen synthase kinase-3beta is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts. *Cardiovascular research*. 2009;83:698-706.
- [7] Chetty C, Bhoopathi P, Lakka SS, Rao JS. MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line. *Oncogene*. 2007;26:7675-83.
- [8] Aragon JP, Condit ME, Bhushan S, Predmore BL, Patel SS, Grinsfelder DB, et al. Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. *Journal of the American College of Cardiology*. 2011;58:2683-91.
- [9] Hearse DJ, Yellon DM, Downey JM. Can beta blockers limit myocardial infarct size? *European heart journal*. 1986;7:925-30.
- [10] Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C, et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. *The American journal of cardiology*. 1962;9:166-81.
- [11] Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D'Agostino RB, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. *JAMA : the journal of the American Medical Association*. 2012;307:1925-33.
- [12] Senges J, Brachmann J, Czygan E, Rizos I, Lengfelder W, Kubler W. Electrophysiological effects of glucose-insulin-potassium on sinus node function in patients with and without sinus node dysfunction. *Cardiovascular research*. 1982;16:566-72.
- [13] Roubille F, Franck-Miclo A, Covinhes A, Lafont C, Cransac F, Combes S, et al. Delayed postconditioning in the mouse heart in vivo. *Circulation*. 2011;124:1330-6.
- [14] Basalay M, Barsukevich V, Mastitskaya S, Mrochek A, Pernow J, Sjoquist PO, et al. Remote ischaemic pre- and delayed postconditioning - similar degree of cardioprotection but distinct mechanisms. *Experimental physiology*. 2012;97:908-17.
- [15] Skyschally A, Gres P, Heusch P, Martin C, Haude M, Erbel R, et al. Preinfarction angina: no interference of coronary microembolization with acute ischemic preconditioning. *Journal of molecular and cellular cardiology*. 2005;39:355-61.